Doc description: Information Disclosure Statement (IDS) Filed

PTO/SB/05e (12-08)
Approved for use through 01/31/2009 OMB 0651-0031
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Filin
	First
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art l
	Exa

	Application Number		10684633				
	Filing Date		2003-10-14				
	First Named Inventor	Micha	hael S. Kopreski				
	Art Unit		1634				
	Examiner Name	Lu, Fi	rank Wei Min				
	Attorney Docket Numb	er	00-1312-L				

	Remove					
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6329179	B1	2001-12-11	Michael Kopreski	
	2	6051374		2000-04-18	Simons, John	
	3	4631130		1986-12-23	Watanabe, Masaharu	
	4	6916634		2005-07-12	Kopreski, Michael	
	5	5506106		1996-04-09	Croce, Carlo	
	6	4874853		1989-10-17	Rossi, John	
	7	6759217		2004-07-06	Kopreski, Michael	
	8	6607898		2003-08-19	Kopreski, Michael	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10684633
	Filing Date		2003-10-14
	First Named Inventor	Micha	ael S. Kopreski
	Art Unit		1634
	Examiner Name	Lu, Fr	rank Wei Min
	Attorney Docket Numb	er	00-1312-L

	9 6794135			2004-09-21	Kopreski, Michael	
	10	6939671		2005-09-06	Kopreski, Michael	
	11	4738927		1988-04-19	Taniguchi, Tadatsugu	
	12	5576178		1996-11-19	Emanuel, Beverly	
	13	6057105	2000-05-02		Hoon, Dave	
	14	4350156		1982-09-21	Malchesky, Paul	
	15	5532220		1996-07-02	Lee, Wen-Hwa	
	16 6344317			2002-02-05	Umovitz	
	17	6001987		1999-12-14	Perron	
	18	5429923		1995-07-04	Seidman	
If you wis	h to a	dd additional U.S. Paten			ease click the Add button.	Add Remove
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	remove

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10684633
Filing Date		2003-10-14
First Named Inventor	Micha	ael S. Kopreski
Art Unit		1634
Examiner Name Lu,		rank Wei Min
Attorney Docket Numb	er	00-1312-L

Examiner Initial*	Cite No	Publication Number	Kind Publication Name of Patentee or Applicant Relevan		Columns, Lines wher ant Passages or Rele Appear					
	1	20040058331		2004-03	1-25	Akagi, Kiwami,				
If you wis	h to a	dd additional U.S. Publi	ished Ap	plication	citatio	n information p	please click the Ad	d buttor	1. Add	
				FOREIG	3N PAT	TENT DOCUM	IENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup>		Kind Code <sup>4</sup>	Publication Date	Name of Patente Applicant of cited Document	e or	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear	
	1	97/35589	wo		A	1997-10-02	Kopreski, Michael			
	2	98/14617	wo		A	1998-04-09	Umovitz, Howard			
	3	99/67397	wo			1999-12-29	Li, En etal.			
If you wisl	h to a	ı dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add	-
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the a (book, magazine, jour publisher, city and/or	nal, seri	al, symp	osium,	catalog, etc), o				Ţŝ
	1	Serra et al. (2001), Neur	rological S	Sciences	22(2): 1	71-173.				
	2	Shen et al. (1995), Proc.	Natl. Ac	ad. Sci. U	J. S. A. 9	92: 6778-6782				

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number 10684633
Filing Date 2003-10-14
First Named Inventor Machael S. Kopresio Art Unit 1634
Examiner Name | Liu. Frank Win Min |
Attorney Docket Number 00-1312-L

	3	Shutack et al. (1968), J. Am. Osleopath. Assoc. 67(9): 1051-1053.	
	4	Spiegelman et al. (1999), The Harvey Lectures No. 64, pp. 1-67.	
	5	Stroun et al. (1978), Cancer Res. 38(10): 3546-3554.	
	6	Tamamiyagi et al. (1996), J. Dermatol. Sci. 11(2): 154-60.	
	7	Urdea et al. (1993), AIDS 7(suppl. 2): S11-S14.	
	8	Rohde et al. (2000), Clin. Cancer Res. 6: 4803-4909.	
	9	Keiler et al. (1993), PCR Methods and Applications 3: 32-38.	
	10	Nolite et al. (1994), J. Clin. Microbiology 32; 519-520.	
	11	Schmidt et al. (1995), J. Med. Virology 47: 153-160.	
	12	Agirulina et al. (1988), Eksp. Onkol (USSR) 10(4), English abstract.	
	13	Schwarz et al. (1995), Res. Virol (Paris) 146(5), English abstract.	

14	Kato et al. (1993), Hepatiology 18(1), abstract.	
15	Glick et al. (1994), Molecular biotechnology: Principles and applications of recombinant DNA, ASM Press: Washington DC. Table of Contents for Molecular Diagnostics (8) and Vaccines and Therapeutic Agents (9).	
16	Persing et al (1993), Diagnostic molecular microbology: Principles and applications, Amer. Soc. Microbol. Washington DC, Table of Contents for Principles of Diagnostic Molecular Microbiology and Vira Pathogens.	
17	Southall et al. (1990), Br. J. Cancer 61: 89-95.	
18	Kopreski et al. (2001), Ann. N. Y. Acad. Sci 945: 172-178.	
19	Yan-Sanders et al. (2002), Cancer Letters 183: 215-220.	
20	Khimani et al. (2005), BioTechniques 38: 739-745.	
21	Schrader et al. (2002), BMC Cancer 2: 32.	
22	Fleischhadrer et al. (2001), Ann. N. Y. Acad. Sci. 945: 179-188.	
23	Burd et al. (1989), Proc. Natl. Acad. Sci. U. S. A. 86: 9788-9792.	
24	Burchill et al. (1995), Br. J. Cancer 71: 278-281.	

	25	Lasheeb et al. (1997), Gentlourinary Medicine 73(4): 303-305.	
	26	Mermin et al. (1991), J. Infectious Diseases 164(4): 769-772.	
	27	Kopreski et al. (2001), Clin. Chem. 47: 962, abstract 9.	
	28	Pelosi et al. (2006), Virchows Arch. 448: 7-15.	
	29	Tahara et al. (1999), Oncogene 18: 1561-1567.	
	30	Dasi et al. (2001), Lab. Investigation 81: 767-769.	
	31	Hasseimann et al. (2001), Oncol. Rep. 8: 115-118.	
	32	Ng et al. (2002), Clin. Chem. 48: 1212-1217.	
	33	Chen et al. (2000), Clin. Cancer Res. 6: 3823-3826.	
	34	Silva et al. (2001), Clin. Canoer Res. 7: 2821-2825.	
	35	Silva et al. (2001), Oncol. Rep. 8: 693-696.	П

36	Gal et al. (2001), Ann. N. Y. Acad. Sci. 945: 192-194.	
37	Durie et al. (2000), Acta Oncol. 39: 789-796.	
38	Mlura et al. (2003), Oncology 64: 430-434.	
39	Wong et al. (2004), J. Clin. Pathol. 57: 766-768.	
40	Ma et al. (2007), Haematologica 92: 170-175.	
41	Arcari et al. (1984), Nucleic Acids Res. 12: 9179-9189.	
42	Rykova et al. (2006), Ann. N. Y. Acad. Sci. 1075; 328-333.	
43	Hernandez et al. (1999), Leukemia 13: 2087-2093.	
44	Zhou et al. (1998), Clin. Cancer Res. 4: 1631-1640.	
45	Zhou et al. (2001), Breast Canoer Research and Treatment 66: 217-224.	
46	Press et al. (1990). (Inconent 5: 953.962)	П

## | INFORMATION DISCLOSURE | Application Number | 10084633 | Filing Date | 2003-10-14 | Filing Date | 2003-10-14 | First Named Inventor | Michael S. Kogreski | Art Unit | 1634 | Examiner Name | Liu, Frank Wel Min | Attoney Docket Number | 00-13124 |

		47	Ng et	t al. (2003), Proc. Natl. Acad. Sci. U. S. A. 100: 4748-4753.					
		48	Baire	ey et al. (2002), Arch. Pathol. Lab. Med. 126: 574-576.					
		49	Gilmo	our et al. (2001), Canoer Res. 61: 2169-2716.					
		50	Reinh	hold et al. (2001), Clin. Chem. 47: 369, abstract 50.					
Ī	If you wisl	h to a	dd add	ditional non-patent literature document citation information plea	ase click the Add b	utton Add			
ľ	EXAMINER SIGNATURE								
Ī	Examiner	Signa	ture	D	ate Considered				
ŀ	*EXAMIN	ER: Ir	itial if	reference considered, whether or not citation is in conformand	ce with MPEP 609	Draw line through	а		

citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. <sup>3</sup> Enter office that issued the document, by the two-letter code (WIPO

Take And Chair Or User 10 years Lockinstrate at wise <u>User Locking or Locking From the State of the State Chair Chair Chair Locking Chair Locking State (Locking State Chair Locking State Chair Chair Locking State Chair Cha</u>